Aethlon Medical Stock Price, News & Analysis

Aethlon Medical, Inc. (AEMD) has announced the treatment of its first patient in a first-in-human Early Feasibility Study (EFS) using the HEMOPURIFIER® for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck at UPMC Hillman Cancer Center, Pittsburgh. The trial aims to assess the safety of the HEMOPURIFIER® and its potential to improve the efficacy of pembrolizumab (KEYTRUDA®) by reducing cancer-associated exosomes. This represents a crucial step in addressing unmet needs in cancer treatment, especially regarding immune suppression caused by tumor-derived exosomes.

Aethlon Medical, Inc. (Nasdaq: AEMD) appointed Dr. Charles J. Fisher, Jr. as CEO effective October 30, 2020, succeeding Dr. Timothy Rodell, who will transition to a consultancy role. Dr. Fisher has significant experience, including leadership roles at Eli Lilly and Abbott Laboratories, and is expected to enhance Aethlon's product development, particularly the Hemopurifier, aimed at treating life-threatening viral infections and cancer. The company is now initiating clinical trials for the Hemopurifier in patients with COVID-19 and advanced cancer.

Aethlon Medical, Inc. (AEMD) reported its financial results for the second quarter ending September 30, 2020. The company has approximately $14.5 million in cash and reported a net loss of about $1.77 million, up from $1.71 million year-over-year. Operating expenses increased by 4.1% to $1.77 million, driven by higher general and administrative costs.

The company is advancing its Hemopurifier device through FDA-approved clinical trials for cancer and COVID-19 treatments. The first trial is open for enrollment in patients with advanced head and neck cancer.

Aethlon Medical, Inc. (AEMD) will release its financial results for Q2 FY2021 on October 28, 2020, at 4:15 PM ET. The results will cover the period ending September 30, 2020. A conference call will follow at 4:30 PM ET, allowing management to discuss the outcomes and recent developments. Interested participants can register online for the conference call or dial in using the toll-free or international numbers provided. Aethlon focuses on unmet health needs, particularly with its Aethlon Hemopurifier®, a device for treating cancer and viral infections.

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology firm, will be presenting at the HC Wainwright 22nd Annual Global Investment Conference on Monday, Sept. 14, 2020, at 2:00 p.m. EDT. The presentation will be led by CEO Timothy C. Rodell and will be available for replay for 90 days post-presentation. Aethlon’s primary focus is the Hemopurifier^®, a breakthrough immunotherapeutic device targeting cancer and life-threatening viral infections. The Hemopurifier aims to reduce tumor-derived exosomes that contribute to immune suppression and metastasis.

Aethlon Medical, Inc. (Nasdaq: AEMD) will present at the LD Micro 500 virtual investor conference on September 3, 2020, at 11:40 AM PT. CEO Timothy C. Rodell, MD, will also hold one-on-one meetings with investors throughout the day. The presentation will be accessible live and later as a replay on Aethlon's website. The LD Micro 500 runs from September 1-4, featuring 500 micro-cap companies. Aethlon's Hemopurifier® is a breakthrough device targeting cancer and viral infections, focusing on depleting tumor-derived exosomes.

Aethlon Medical, Inc. (AEMD) announced its financial results for Q1 2020, reporting a net loss of approximately $1.4 million, reduced from $2.1 million in Q1 2019. Operating expenses decreased by 12% to $1.4 million, attributed to lower payroll and professional fees. Aethlon continues developing its Hemopurifier®, now entering clinical trials for advanced cancer and SARS-CoV-2 treatment. The company received a $3.5 million NIH grant to support exosome research. As of June 30, 2020, it reported a cash balance of $15.7 million.

Aethlon Medical, Inc. (AEMD) announced a $3.5 million grant from the NIH's NIDCR for a collaborative study on head and neck cancer with the UPMC Hillman Cancer Center. This project will investigate the role of tumor-derived exosomes and assess the impact of Aethlon's Hemopurifier device in enhancing immune therapy responses. Led by Drs. Theresa Whiteside and Annette Marleau, the five-year study aims to improve treatment outcomes for patients suffering from recurrent and metastatic head and neck cancer.

Aethlon Medical, Inc. (AEMD) announced it will release its financial results for Q1 FY2021 on August 11, 2020, at 4:15 PM Eastern Time. This is for the quarter ending June 30, 2020. A conference call will follow at 4:30 PM Eastern Time, where management will discuss the results and recent developments. The call will include a Q&A session. The Aethlon Hemopurifier, a Breakthrough Device for cancer and viral infections, continues to progress in addressing critical health needs.